The COVID-19 omicron variant has diminished the efficacy of the US's most prominent antibody treatments. As the genome of this virus constantly…
McAlinden Research PartnersJanuary 4, 2022
Cruise line stocks remain well below pre-pandemic valuations, but it appears a recovery is starting to accelerate across the industry.…
McAlinden Research PartnersSeptember 27, 2021
The cruise industry is slowly approaching a return to normal, finally returning to service amid pent-up demand for leisure travel. After…
McAlinden Research PartnersJune 14, 2021
In a market that has has become a sea of expensive growth stocks, the UK stands out as an island of…
McAlinden Research PartnersJanuary 25, 2021
Just days after AMC and Cineworld laid out plans for new financing to ward off the looming threat of insolvency, Warner…
McAlinden Research PartnersDecember 8, 2020
While the US and Europe continue to battle the pandemic, most countries in the Asia-Pacific region have managed to supress…
McAlinden Research PartnersOctober 29, 2020
With election day less than a week away, we dive into polling, contributions, and alternative data to generate a final…
McAlinden Research PartnersOctober 29, 2020
Summary: New data shows developments in robotics and automation technology continue to accelerate as a result of COVID-19. Though the virus dealt a blow…
McAlinden Research PartnersOctober 21, 2020
Drugstore chains already faced secular headwinds heading into 2020, as competition from online sellers, independent prescription delivery services, and retail…
McAlinden Research PartnersOctober 19, 2020
